Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD30-Positive Peripheral T-Cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02497131
What this trial is testing

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Who this might be right for
Lymphatic Diseases
Fondazione Italiana Linfomi - ETS 25
Early research (Phase 1)Active Not RecruitingNCT04288726
What this trial is testing

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Who this might be right for
Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeClassical Hodgkin Lymphoma
Baylor College of Medicine 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT03113500
What this trial is testing

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Who this might be right for
Adult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-Positive+8 more
City of Hope Medical Center 48
Testing effectiveness (Phase 2)Study completedNCT04101331
What this trial is testing

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Who this might be right for
Peripheral T Cell LymphomaTransformed Mycosis Fungoides
Affimed GmbH 108
Early research (Phase 1)Not Yet RecruitingNCT07729397
What this trial is testing

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)Hodgkin LymphomaPeripheral T-cell Lymphoma (PTCL)+2 more
The Methodist Hospital Research Institute 21
Testing effectiveness (Phase 2)Study completedNCT03192202
What this trial is testing

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Who this might be right for
Lymphoma, T-Cell, Cutaneous
Ahmed Sawas 18
Testing effectiveness (Phase 2)Ended earlyNCT05883449
What this trial is testing

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaPeripheral T Cell Lymphoma
Affimed GmbH 25
Testing effectiveness (Phase 2)UnknownNCT05316246
What this trial is testing

Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

Who this might be right for
NK/T Cell Lymphoma Nos
Shanghai Zhongshan Hospital 40
Early research (Phase 1)WithdrawnNCT04952584
What this trial is testing

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Who this might be right for
Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeClassical Hodgkin Lymphoma
Baylor College of Medicine
Testing effectiveness (Phase 2)Study completedNCT04569032
What this trial is testing

Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Who this might be right for
Peripheral T-cell Lymphoma
Seagen, a wholly owned subsidiary of Pfizer 82